Personal information

Websites & social links

Twitter
Google Scholar
Lung Cancer Foundation of America: Profile

Keywords

immunotherapy, non-small cell lung cancer, immune-related adverse event, pneumonitis, clinical trial

Countries

Ireland

Activities

Collapse all

Employment (4)

Royal College of Surgeons in Ireland: Dublin, IE

2020-09-01 to present | Honorary Senior Lecturer (Medicine)
Employment
Source: Self-asserted source
Jarushka Naidoo

Beaumont Hospital: Dublin, IE

2020-09-01 to present | Consultant Medical Oncologist (Oncology)
Employment
Source: Self-asserted source
Jarushka Naidoo

Johns Hopkins University: Baltimore, Maryland, US

2019-09-01 to present | Adjunct Assistant Professor (Oncology)
Employment
Source: Self-asserted source
Jarushka Naidoo

Johns Hopkins University: Baltimore, Maryland, US

2015-09-01 to 2020-08-15 | Assistant Professor of Oncology (Oncology)
Employment
Source: Self-asserted source
Jarushka Naidoo

Education and qualifications (3)

Royal College of Physicians of Ireland: Dublin, IE

2017-01-30 to present | Completion of Subspecialist Training: Medical Oncology (Medicine)
Qualification
Source: Self-asserted source
Jarushka Naidoo

Johns Hopkins University: Baltimore, Maryland, US

2017-07-01 to 2019-07-01 | Masters of Health Science (School of Public Health)
Qualification
Source: Self-asserted source
Jarushka Naidoo

Trinity College Dublin: Dublin, Dublin, IE

2000-09-01 to 2006-06-01 | Medicine (MB BCH) (Health Sciences)
Qualification
Source: Self-asserted source
Jarushka Naidoo

Professional activities (25)

Cancer Trials Ireland: Dublin, IE

2020-10-01 to present | Lung DSSG Chair
Membership
Source: Self-asserted source
Jarushka Naidoo

Royal College of Surgeons of Ireland: Dublin, Dublin, IE

2020-09-01 to present | Honorary Senior Lecturer (Medicine)
Invited position
Source: Self-asserted source
Jarushka Naidoo

Johns Hopkins University: Baltimore, Maryland, US

2020-09-01 to present | Adjunct Assistant Professor (Oncology)
Invited position
Source: Self-asserted source
Jarushka Naidoo

European Thoracic Oncology Platform: Brno, CZ

2020-09-01 to present | Full Member (Oncology)
Membership
Source: Self-asserted source
Jarushka Naidoo

NRG Oncology: Philadelphia, Pennsylvania, US

2018-07-01 to present | Immunotherapy Subcommittee chair
Membership
Source: Self-asserted source
Jarushka Naidoo

ECOG-ACRIN Cancer Research Group: Philadelphia, Pennsylvania, US

2015-09-01 to present | Full member (Thoracic Oncology Committee, Symptom Science committee)
Membership
Source: Self-asserted source
Jarushka Naidoo

Society for Immunotherapy of Cancer: Milwaukee, WI, US

2013-09-01 to present | Full member
Membership
Source: Self-asserted source
Jarushka Naidoo

American Association for Cancer Research: Philadelphia, PA, US

2013-07-01 to present | Full Member
Membership
Source: Self-asserted source
Jarushka Naidoo

International Association for the Study of Lung Cancer: Aurora, CO, US

2010-09-01 to present | Full Member
Service
Source: Self-asserted source
Jarushka Naidoo

European Society for Medical Oncology: Lugano, Ticino, CH

2010-07-01 to present | Full member
Membership
Source: Self-asserted source
Jarushka Naidoo

Cancer Trials Ireland: Dublin, IE

2010-07-01 to present | Full Member
Membership
Source: Self-asserted source
Jarushka Naidoo

American Society of Clinical Oncology: Alexandria, VA, US

2010-07-01 to present | Full Member (Oncology)
Membership
Source: Self-asserted source
Jarushka Naidoo

National Comprehensive Cancer Network: Plymouth Meeting, PA, US

2017-07-01 to 2020-08-15 | Committee Member
Membership
Source: Self-asserted source
Jarushka Naidoo

Johns Hopkins University: Baltimore, Maryland, US

2015-09-01 to 2020-08-15 | Assistant Professor (Oncology)
Invited position
Source: Self-asserted source
Jarushka Naidoo

American Society of Clinical Oncology: Alexandria, VA, US

2020-06-01 | ASCO Leadership Development Program, Class of 2020 (Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

American Society of Clinical Oncology: Alexandria, VA, US

2017-06-01 | Best of JCO 2017 (Journal of Clinical Oncology )
Distinction
Source: Self-asserted source
Jarushka Naidoo

American Association for Cancer Research: PA, PA, US

2017-06-01 | Best of Cancer Immunology Research 2017 (Cancer Immunology Research)
Distinction
Source: Self-asserted source
Jarushka Naidoo

ARC Young Investigator's Forum: Houston, Texas, US

2016-09-01 | Young Investigator Award (Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

prIME Oncology: Atlanta, GA, US

2016-01-30 | Young Investigator Award (Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

ARC Young Investigator's Forum: Houston, Texas, US

2015-09-01 | Young Investigator Award: Best Presentation (Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

Conquer Cancer Foundation: Alexandria, Virginia, US

2015-06-01 | Merit Award (American Society of Clinical Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

Memorial Sloan-Kettering Cancer Center: NY, NY, US

2013-07-01 | Advanced Medical Oncology Fellowship Scholarship (Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

Irish Society of Medical Oncology: Dublin, Dublin, IE

2013-02-10 | Best Oral Presentation at Annual Meeting (Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

Irish Society of Medical Oncology: Dublin, Dublin, IE

2009-01-30 | Best Oral Presentation, Annual Meeting (Oncology)
Distinction
Source: Self-asserted source
Jarushka Naidoo

Trinity College Dublin: Dublin, Dublin, IE

2002-06-01 | Foundation Scholarship Winner (Medicine and Health Sciences)
Distinction
Source: Self-asserted source
Jarushka Naidoo

Funding (2)

Tailoring Lung Cancer Screening for Ireland: Using Existing Datasets to Generate Evidence-Based Recommendations for Health Policy

2024-10-01 to 2026-09-30 | Grant
Health Research Board (Dublin, IE)
GRANT_NUMBER:

SDAP-2023-033
Source: check_circle
Health Research Board

Microbial Determinants of Response and Toxicity to Immunotherapy for NSCLC

2020-01 to 2023-01 | Grant
International Association for the Study of Lung Cancer (CO, CO, US)
GRANT_NUMBER: LCFA
Source: Self-asserted source
Jarushka Naidoo

Works (50 of 74)

Items per page:
Page 1 of 2

Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Cancers
2024-08 | Journal article | Author
DOI: 10.3390/cancers16162779
Contributors: Pernelle Lavaud; Martina Bortolot; Lodovica Zullo; David O’Reilly; Jarushka Naidoo; Giannis Mountzios; Olaf Mercier; Lizza Hendriks; Jordi Remon
Source: check_circle
Multidisciplinary Digital Publishing Institute

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.

JAMA oncology
2020-10-29 | Journal article
DOI: 10.1001/jamaoncol.2020.5012
PMID: 33119034
Source: Self-asserted source
Jarushka Naidoo

Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)
2020-09-05 | Journal article
DOI: 10.1016/j.lungcan.2020.08.022
PMID: 32958455
Source: Self-asserted source
Jarushka Naidoo

Information Visualization Platform for Postmarket Surveillance Decision Support.

Drug safety
2020-09-01 | Journal article
DOI: 10.1007/s40264-020-00945-0
PMID: 32445187
Source: Self-asserted source
Jarushka Naidoo

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.

Journal for immunotherapy of cancer
2020-09-01 | Journal article
DOI: 10.1136/jitc-2020-001282
PMID: 32929052
PMC: PMC7488786
Source: Self-asserted source
Jarushka Naidoo

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.

The Lancet. Oncology
2020-08-01 | Journal article
DOI: 10.1016/s1470-2045(20)30107-8
PMID: 32758477
Source: Self-asserted source
Jarushka Naidoo

Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer.

JCO oncology practice
2020-08-01 | Journal article
DOI: 10.1200/op.20.00573
PMID: 32780984
Source: Self-asserted source
Jarushka Naidoo

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities.

The oncologist
2020-07-23 | Journal article
DOI: 10.1634/theoncologist.2020-0266
PMID: 32701167
PMC: PMC7648326
Source: Self-asserted source
Jarushka Naidoo

Chronic immune checkpoint inhibitor pneumonitis.

Journal for immunotherapy of cancer
2020-06-01 | Journal article
DOI: 10.1136/jitc-2020-000840
PMID: 32554618
PMC: PMC7304886
Source: Self-asserted source
Jarushka Naidoo

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management.

Journal for immunotherapy of cancer
2020-06-01 | Journal article
DOI: 10.1136/jitc-2020-000984
PMID: 32554619
PMC: PMC7316105
Source: Self-asserted source
Jarushka Naidoo

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Lancet (London, England)
2020-05-28 | Journal article
DOI: 10.1016/s0140-6736(20)31187-9
PMID: 32473681
PMC: PMC7255743
Source: Self-asserted source
Jarushka Naidoo

Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.

Current oncology reports
2020-05-16 | Journal article
DOI: 10.1007/s11912-020-00920-z
PMID: 32415399
Source: Self-asserted source
Jarushka Naidoo

Principles of Immunotherapy in Non-Small Cell Lung Cancer.

Thoracic surgery clinics
2020-05-01 | Journal article
DOI: 10.1016/j.thorsurg.2020.01.009
PMID: 32327177
Source: Self-asserted source
Jarushka Naidoo

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.

Clinical lung cancer
2020-03-09 | Journal article
DOI: 10.1016/j.cllc.2020.02.025
PMID: 32576443
Source: Self-asserted source
Jarushka Naidoo

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.

Journal of the National Comprehensive Cancer Network : JNCCN
2020-03-01 | Journal article
DOI: 10.6004/jnccn.2020.0012
PMID: 32135517
Source: Self-asserted source
Jarushka Naidoo

Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer.

Nature cancer
2020-01-13 | Journal article
DOI: 10.1038/s43018-019-0008-8
PMID: 32984843
PMC: PMC7514475
Source: Self-asserted source
Jarushka Naidoo

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2019-12-04 | Journal article
DOI: 10.1200/jco.19.01674
PMID: 31800340
Source: Self-asserted source
Jarushka Naidoo

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2019-11-21 | Journal article
DOI: 10.1158/1078-0432.ccr-19-2931
PMID: 31754049
PMC: PMC7073288
Source: Self-asserted source
Jarushka Naidoo

Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer.

Clinical lung cancer
2019-11-06 | Journal article
DOI: 10.1016/j.cllc.2019.10.009
PMID: 31787546
Source: Self-asserted source
Jarushka Naidoo

Successful Treatment of Scar Pain with Scrambler Therapy.

Cureus
2019-10-14 | Journal article
DOI: 10.7759/cureus.5903
PMID: 31777690
PMC: PMC6853271
Source: Self-asserted source
Jarushka Naidoo

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.

Annals of the rheumatic diseases
2019-09-20 | Journal article
DOI: 10.1136/annrheumdis-2019-216109
PMID: 31540935
Source: Self-asserted source
Jarushka Naidoo

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.

American journal of respiratory and critical care medicine
2019-09-01 | Journal article
DOI: 10.1164/rccm.201906-1202st
PMID: 31518182
PMC: PMC6775885
Source: Self-asserted source
Jarushka Naidoo

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.

Journal of oncology practice
2019-08-06 | Journal article
DOI: 10.1200/jop.18.00703
PMID: 31386608
PMC: PMC6743220
Source: Self-asserted source
Jarushka Naidoo

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

The Journal of clinical investigation
2019-07-16 | Journal article
DOI: 10.1172/jci128654
PMID: 31310589
PMC: PMC6763233
Source: Self-asserted source
Jarushka Naidoo

Immune-Related Adverse Events: A Case-Based Approach.

Frontiers in oncology
2019-06-20 | Journal article
DOI: 10.3389/fonc.2019.00530
PMID: 31293970
PMC: PMC6598598
Source: Self-asserted source
Jarushka Naidoo

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2019-06-04 | Journal article
DOI: 10.1200/jco.19.00320
PMID: 31163011
PMC: PMC6800279
Source: Self-asserted source
Jarushka Naidoo

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Journal of the National Comprehensive Cancer Network : JNCCN
2019-06-01 | Journal article
DOI: 10.6004/jnccn.2018.7268
PMID: 31200355
Source: Self-asserted source
Jarushka Naidoo

Genome-wide cell-free DNA fragmentation in patients with cancer.

Nature
2019-05-29 | Journal article
DOI: 10.1038/s41586-019-1272-6
PMID: 31142840
PMC: PMC6774252
Source: Self-asserted source
Jarushka Naidoo

Lung cancer and family-centered concerns.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2019-05-07 | Journal article
DOI: 10.1007/s00520-019-04839-5
PMID: 31065838
Source: Self-asserted source
Jarushka Naidoo

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Cardiovascular research
2019-04-01 | Journal article
DOI: 10.1093/cvr/cvz026
PMID: 30715219
PMC: PMC6452314
Source: Self-asserted source
Jarushka Naidoo

Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.

Clinical lung cancer
2019-03-28 | Journal article
DOI: 10.1016/j.cllc.2019.02.018
PMID: 31031204
Source: Self-asserted source
Jarushka Naidoo

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Journal for immunotherapy of cancer
2019-03-06 | Journal article
DOI: 10.1186/s40425-019-0547-7
PMID: 30841906
PMC: PMC6402146
Source: Self-asserted source
Jarushka Naidoo

Management of Immunotherapy-Related Toxicities, Version 1.2019.

Journal of the National Comprehensive Cancer Network : JNCCN
2019-03-01 | Journal article
DOI: 10.6004/jnccn.2019.0013
PMID: 30865922
Source: Self-asserted source
Jarushka Naidoo

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Journal for immunotherapy of cancer
2019-02-11 | Journal article
DOI: 10.1186/s40425-018-0492-x
PMID: 30744692
PMC: PMC6371497
Source: Self-asserted source
Jarushka Naidoo

Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

Cancer research
2018-12-20 | Journal article
DOI: 10.1158/0008-5472.can-18-1082
PMID: 30573519
PMC: PMC6481620
Source: Self-asserted source
Jarushka Naidoo

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Cancer research
2018-12-12 | Journal article
DOI: 10.1158/0008-5472.can-18-1127
PMID: 30541742
PMC: PMC6432636
Source: Self-asserted source
Jarushka Naidoo

An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition.

The Journal of clinical investigation
2018-12-10 | Journal article
DOI: 10.1172/jci125800
PMID: 30530990
PMC: PMC6307975
Source: Self-asserted source
Jarushka Naidoo

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2018-11-30 | Journal article
DOI: 10.1016/j.jtho.2018.11.016
PMID: 30503891
Source: Self-asserted source
Jarushka Naidoo

PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.

Journal of thoracic disease
2018-11-01 | Journal article
DOI: 10.21037/jtd.2018.09.46
PMID: 30631548
PMC: PMC6297512
Source: Self-asserted source
Jarushka Naidoo

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Journal for immunotherapy of cancer
2018-10-11 | Journal article
DOI: 10.1186/s40425-018-0417-8
PMID: 30305172
PMC: PMC6180387
Source: Self-asserted source
Jarushka Naidoo

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2018-09-26 | Journal article
DOI: 10.1016/j.jtho.2018.08.2035
PMID: 30267842
Source: Self-asserted source
Jarushka Naidoo

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.

Chest
2018-09-04 | Journal article
DOI: 10.1016/j.chest.2018.08.1048
PMID: 30189190
PMC: PMC6335259
Source: Self-asserted source
Jarushka Naidoo

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.

Current treatment options in oncology
2018-08-13 | Journal article
DOI: 10.1007/s11864-018-0562-9
PMID: 30101402
PMC: PMC7102206
Source: Self-asserted source
Jarushka Naidoo

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.

Therapeutic advances in medical oncology
2018-07-13 | Journal article
DOI: 10.1177/1758835918778297
PMID: 30023006
PMC: PMC6047239
Source: Self-asserted source
Jarushka Naidoo

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity.

Cancer immunology research
2018-06-12 | Journal article
DOI: 10.1158/2326-6066.cir-18-0129
PMID: 29895573
PMC: PMC6072595
Source: Self-asserted source
Jarushka Naidoo

Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling.

Journal of the National Comprehensive Cancer Network : JNCCN
2018-05-01 | Journal article
DOI: 10.6004/jnccn.2017.7203
PMID: 29752320
Source: Self-asserted source
Jarushka Naidoo

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

The New England journal of medicine
2018-04-16 | Journal article
DOI: 10.1056/nejmoa1716078
PMID: 29658848
PMC: PMC6223617
Source: Self-asserted source
Jarushka Naidoo

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Seminars in arthritis and rheumatism
2018-03-22 | Journal article
DOI: 10.1016/j.semarthrit.2018.02.011
PMID: 29573850
PMC: PMC6150859
Source: Self-asserted source
Jarushka Naidoo

Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy.

Practical radiation oncology
2018-01-31 | Journal article
DOI: 10.1016/j.prro.2018.01.004
PMID: 29960625
Source: Self-asserted source
Jarushka Naidoo

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

International journal of radiation oncology, biology, physics
2017-12-05 | Journal article
DOI: 10.1016/j.ijrobp.2017.11.041
PMID: 29485071
Source: Self-asserted source
Jarushka Naidoo
Items per page:
Page 1 of 2

Peer review (19 reviews for 8 publications/grants)

Review activity for Clinical lung cancer. (3)
Review activity for European journal of cancer. (1)
Review activity for Immuno-oncology technology. (2)
Review activity for Journal for immunotherapy of cancer. (3)
Review activity for Lung cancer. (5)
Review activity for Nature communications (3)
Review activity for Nature reviews. (1)
Review activity for The lancet. (1)
How many people are using ORCID?